Meeting Minutes

Date: Wednesday June 26, 2024  
Time: 11:00 AM – 11:30 AM  
Location: Zoom

Members Present:  
1. Thea Brabb, Comparative Medicine (Animal Containment Expert)  
2. Jason Cantera (Community Member)  
3. Lesley Colby, Comparative Medicine (Animal Containment Expert)  
4. Erin Heiniger, Department of Bioengineering (Laboratory Specialist)  
5. Richard Grant, Washington National Primate Research Center  
6. Kevin Hybiske, Allergy and Infectious Diseases (IBC Vice Chair)  
7. David Koelle, Allergy and Infectious Diseases  
8. Stephen Libby, Laboratory Medicine (Animal Containment Expert)  
9. Scott Meschke, Environmental & Occupational Health Sciences  
10. Jennifer Nemhauser, Department of Biology (Plant Expert)  
11. Susan Parazzoli (Community Member)  
12. Jason Smith, Microbiology (IBC Chair)  
13. Paul Swenson, Seattle-King Co. Dept. of Public Health (Community Member)

Commonly Used Abbreviations:  
AAV: adeno-associated viral vector  
BSL: biosafety level  
BSL-2w/3: BSL-2 with BSL-3 practices  
BSO: Biosafety officer  
BUA: Biological Use Authorization  
DURC: Dual Use Research of Concern  
IACUC: Institutional Animal Care and Use Committee  
IBC: Institutional Biosafety Committee  
iPSCs: induced pluripotent stem cells  
NHP: non-human primate  
NIH: National Institutes of Health  
PI: Principal Investigator  
rDNA: Recombinant or synthetic DNA/RNA  
RG: Risk Group  
SOP: standard operating procedure  
Source material: blood, tissue, body fluids, and cell lines
1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 11:00 a.m. A quorum was present.

2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **DURC REPORT**
   - The DURC Institutional Review Entity (IRE), a subcommittee of the IBC, reviewed three DURC applications. None of the three projects meet the DURC definition.
   - One new project involves drug resistance studies with Risk Group 2 human coronaviruses; no genetic modifications are involved. The DURC IRE voted that the third DURC experimental effect of conferring resistance to therapeutic interventions does apply, but the overall project does not meet the DURC definition.
   - A new project proposed surveying and characterizing highly pathogenic avian influenza viruses from human and animal clinical samples, and then evaluating cellular response to infection, antiviral treatment efficacy, and inactivation protocol efficacy. This project does not meet the DURC definition.
   - One renewal project involved use of botulinum neurotoxin. This project does not meet the DURC definition.
   - The IBC Chair sought a motion to approve this month’s DURC Report.
   - A member made a motion to approve this month’s DURC Report. Another member seconded the motion.
   - The Committee unanimously voted to approve this month’s DURC Report.

10. **ISSUES FROM THE FLOOR & PUBLIC COMMENTS:** There were no issues from the floor, and no public comments.

11. **MEETING ADJOURNED AT APPROXIMATELY 11:13 AM.**